Tumor treating fields are emerging as a promising option for treating a range of cancer types. Here’s a look at the evidence ...

“Olomorasib, in combination with pembrolizumab, has demonstrated significant efficacy and a manageable safety profile in patients with KRAS G12C-mutant advanced/metastatic NSCLC, including patients ...

Bayer’s sevabertinib picks up a second-line indication for HER2-mutated disease, joining Boehringer’s zongertinib on the US ...

While this panel has grown in recent years, many experts believe additional biomarkers should also be incorporated as ...

Comprehensive biomarker testing is central to the management of metastatic non-small cell lung cancer (NSCLC). Widespread ...

Immunotherapy-chemotherapy combination of eftilagimod alfa (efti) and paclitaxel led to strong objective response rates and immune activation in ...

Enfortumab vedotin (EV) in non-squamous and squamous non–small cell lung cancer (NSCLC) cohorts of EV-202. High-dose furmonertinib in patients with EGFR-mutated non-small cell lung cancer and ...

—This study demonstrated that implementing a standardized approach to biomarker testing, including provider education, EHR templates, and order sets, increased comprehensive biomarker testing rates in ...

Magrolimab plus docetaxel improved outcomes in metastatic NSCLC patients with high CD47 expression, showing a median PFS of 8.9 months versus 2.6 months for lower expression. The ELEVATELung&UC trial ...

In November 2025, the U.S. Food and Drug Administration (FDA) issued several approvals across oncology and supportive care.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced detailed results from the Phase 3 EVOKE-01 study that will be presented during an oral session (Abstract ...

Over the past two decades, thoracic oncology has undergone a profound transformation, moving from limited chemotherapy ...